Company Overview of Boston Therapeutics, Inc.
Boston Therapeutics, Inc. focuses on the development, manufacture, and commercialization of therapeutic drugs based on complex carbohydrate chemistry to address unmet medical needs in diabetes and inflammatory diseases. It offers SUGARDOWN, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. The company’s product pipeline includes BTI-320, a non-systemic chewable therapeutic compound, which has completed a Phase II clinical trial to reduce post-meal glucose elevation; IPOXYN, an injectable anti-necrosis drug candidate for the treatment of lower limb ischemia associated with diabetes; and OxyFex for use as an oxygen delivery agent in ve...
1750 Elm Street
Manchester, NH 03104
Founded in 2009
Key Executives for Boston Therapeutics, Inc.
Total Annual Compensation: $71.7K
Chief Financial Officer
Total Annual Compensation: $68.1K
Compensation as of Fiscal Year 2013.
Boston Therapeutics, Inc. Key Developments
Boston Therapeutics, Inc. Presents at 8th Annual OneMedForum 2015, Jan-13-2015 09:15 AM
Dec 19 14
Boston Therapeutics, Inc. Presents at 8th Annual OneMedForum 2015, Jan-13-2015 09:15 AM. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States. Speakers: David Platt, Founder, Chairman, Chief Executive Officer and Treasurer.
Boston Therapeutics, Inc. Announces FDA Acceptance of IND to Initiate a Clinical Trial of BTI-320 to Treat Type ll Diabetes and Weight Loss
Dec 10 14
Boston Therapeutics, Inc. announced that the U.S. Food and Drug Administration has accepted the company's Investigational New Drug Application for BTI-320 to treat Type 2 diabetes and weight management. The primary endpoints for the multicenter trial are the mean change in Hemoglobin A1c (HbA1c) and weight loss. The Joslin Diabetes Center in Boston will be the lead clinic in the trial, which is planned to begin in the first quarter of 2015. This study is being designed as a randomized, placebo-controlled, double-blind, international multicenter study with two treatment arms. It will evaluate the effect of BTI-320 in addition to current treatment with metformin, Dipeptidyl peptidase-4 inhibitors (DPP-4), sulfonylureas and/or long-acting insulin analog on glucose control in patients with Type 2 diabetes. The primary efficacy endpoint of the trial is the mean change in HbA1c levels from baseline at 24 weeks. The study will be conducted at number of international centers located in the U.S., Europe, Asia and Australia. Up to 360 subjects will be enrolled and treated in the study.
Boston Therapeutics and Sugardown Company Ltd. Expand Agreement to Market sugardown(R) in 12 Additional Countries in Asia
Nov 21 14
Boston Therapeutics, Inc. and Advance Pharmaceutical Company Ltd., via its subsidiary Sugardown Company Ltd. of Hong Kong, have agreed to expand their marketing agreement for Boston Therapeutics' sugardown(R) to include 12 additional countries in Asia. The territory expansion comes as a result of the continued regulatory filings and marketing clearance authorizations that are being granted as Advance continues its market registration expansion. In connection with this development, Boston Therapeutics received a purchase order from Sugardown Company Ltd. for 60,000 units to be tentatively shipped by the end of the first quarter of 2015. Under the terms of the original agreement, SugarDown Company Ltd. can market sugardown(R) in China, Hong Kong and Macau. The new agreement expands the marketing initiative to Korea, Taiwan, Singapore, Thailand, Malaysia, Vietnam, Philippines, Myanmar, Indonesia, Laos, Brunei and Cambodia. Advance has already been granted marketing approval in Singapore, Macau, and Korea along with Hong Kong. The main China registration will enter the clinical testing phase early in 2015 with a projected approval tentatively set for later in the year.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|